Mainz Tangible Assets Book Value per Share from 2010 to 2024

MYNZ Stock  USD 0.90  0.03  3.23%   
Check Mainz Biomed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mainz main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 909.7 K or Interest Expense of 419.9 K, as well as many exotic indicators such as Price To Sales Ratio of 19.99, Dividend Yield of 0.0 or PTB Ratio of 6.09. Mainz financial statements analysis is a perfect complement when working with Mainz Biomed Valuation or Volatility modules.
  
This module can also supplement various Mainz Biomed Technical models . Check out the analysis of Mainz Biomed Correlation against competitors.

About Mainz Biomed Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Mainz Biomed income statement, its balance sheet, and the statement of cash flows. Mainz Biomed investors use historical funamental indicators, such as Mainz Biomed's Tangible Assets Book Value per Share, to determine how well the company is positioned to perform in the future. Although Mainz Biomed investors may use each financial statement separately, they are all related. The changes in Mainz Biomed's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Mainz Biomed's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Mainz Biomed Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Mainz Biomed. Please read more on our technical analysis and fundamental analysis pages.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic and research use only tests for clinical diagnostics in human genetics. The company was founded in 2008 and is based in Mainz, Germany. Mainz Biomed is traded on NASDAQ Exchange in the United States.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Mainz Biomed BV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mainz Biomed's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mainz Biomed Bv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mainz Biomed Bv Stock:
Check out the analysis of Mainz Biomed Correlation against competitors.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Mainz Stock analysis

When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Equity Valuation
Check real value of public entities based on technical and fundamental data
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Is Mainz Biomed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mainz Biomed. If investors know Mainz will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mainz Biomed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.62)
Revenue Per Share
0.055
Quarterly Revenue Growth
0.111
Return On Assets
(0.93)
Return On Equity
(3.03)
The market value of Mainz Biomed BV is measured differently than its book value, which is the value of Mainz that is recorded on the company's balance sheet. Investors also form their own opinion of Mainz Biomed's value that differs from its market value or its book value, called intrinsic value, which is Mainz Biomed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mainz Biomed's market value can be influenced by many factors that don't directly affect Mainz Biomed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mainz Biomed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mainz Biomed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mainz Biomed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.